Journal of Pathology and Translational Medicine

Original Articles

Histopathologic classification and immunohistochemical features of papillary renal neoplasm with potential therapeutic targets: Jeong Hwan Park, Su-Jin Shin, Hyun-Jung Kim, Sohee Oh, Yong Mee Cho; J Pathol Transl Med. 2024;58(6):321-330. Published online September 12, 2024; DOI: https://doi.org/10.4132/jptm.2024.07.31

1,737 View
327 Download
1 Crossref

Background
Papillary renal cell carcinoma (pRCC) is the second most common histological subtype of renal cell carcinoma and is considered a morphologically and molecularly heterogeneous tumor. Accurate classification and assessment of the immunohistochemical features of possible therapeutic targets are needed for precise patient care. We aimed to evaluate immunohistochemical features and possible therapeutic targets of papillary renal neoplasms
Methods
We collected 140 papillary renal neoplasms from three different hospitals and conducted immunohistochemical studies on tissue microarray slides. We performed succinate dehydrogenase B, fumarate hydratase, and transcription factor E3 immunohistochemical studies for differential diagnosis and re-classified five cases (3.6%) of papillary renal neoplasms. In addition, we conducted c-MET, p16, c-Myc, Ki-67, p53, and stimulator of interferon genes (STING) immunohistochemical studies to evaluate their pathogenesis and value for therapeutic targets.
Results
We found that c-MET expression was more common in pRCC (classic) (p = .021) among papillary renal neoplasms and Ki-67 proliferation index was higher in pRCC (not otherwise specified, NOS) compared to that of pRCC (classic) and papillary neoplasm with reverse polarity (marginal significance, p = .080). Small subsets of cases with p16 block positivity (4.5%) (pRCC [NOS] only) and c-Myc expression (7.1%) (pRCC [classic] only) were found. Also, there were some cases showing STING expression and those cases were associated with increased Ki-67 proliferation index (marginal significance, p = .063).
Conclusions
Our findings suggested that there are subsets of pRCC with c-MET, p16, c-MYC, and STING expression and those cases could be potential candidates for targeted therapy.

Citations

Citations to this article as recorded by

Tissue-Based Biomarkers Important for Prognostication and Management of Genitourinary Tumors, Including Surrogate Markers of Genomic Alterations
Leonie Beauchamp, Shreeya Indulkar, Eric Erak, Mohammad Salimian, Andres Matoso
Surgical Pathology Clinics.2025; 18(1): 175. CrossRef

Clear Cell Papillary Renal Cell Carcinoma: A Report of 15 Cases Including Three Cases of Concurrent Other-Type Renal Cell Carcinomas: Jeong Hwan Park, Cheol Lee, Ja Hee Suh, Kyung Chul Moon; Korean J Pathol. 2012;46(6):541-547. Published online December 26, 2012; DOI: https://doi.org/10.4132/KoreanJPathol.2012.46.6.541

8,263 View
61 Download
23 Crossref

Abstract PDF

Background

Clear cell papillary renal cell carcinoma (CCPRCC) is a recently established subtype of renal epithelial tumor. The aim of this study was to identify the diagnostic criteria of CCPRCC with an emphasis on immunohistochemical studies, and to report three cases with concurrent other-type renal cell carcinoma (RCC).

Methods

A total of 515 RCC patients that consecutively underwent surgical resection at Seoul National University Hospital from 1 January 2010 to 31 December 2011 were screened. Each case was reviewed based on the histologic features and was evaluated immunohistochemically.

Results

A total of 15 CCPRCCs were identified, which composed 2.9% of the total RCCs. The mean age was 52 years, and the average tumor size was 1.65 cm. All 15 cases showed low nuclear grade, no lymph node metastasis and no distant metastasis. The CCPRCCs showed variable architectural patterns including cystic, trabecular, papillary, and acinar. All of the cases showed moderate to intense immunoreactivity for cytokeratin 7 (CK7). CD10 was negative or showed focal weak positivity. Three cases had concurrent other-type RCC, including a clear cell RCC and an acquired cystic disease-associated RCC.

Conclusions

The strong CK7 and negative or focal weak CD10 expression will be useful for the diagnosis of CCPRCC.

Citations

Citations to this article as recorded by

Vascular, adipose tissue, and/or calyceal invasion in clear cell tubulopapillary renal cell tumour: potentially problematic diagnostic scenarios
Ankur R Sangoi, Harrison Tsai, Lara Harik, Jonathan Mahlow, Maria Tretiakova, Sean R Williamson, Michelle S Hirsch
Histopathology.2024; 84(7): 1167. CrossRef
Clinical features and Surgical Outcome of Clear Cell Papillary Renal Cell Tumor: result from a prospective cohort
Si Hyun Kim, Jang Hee Han, Seung-hwan Jeong, Hyeong Dong Yuk, Ja Hyeon Ku, Cheol Kwak, Hyeon Hoe Kim, Kyung Chul Moon, Chang Wook Jeong
BMC Urology.2023;[Epub] CrossRef
Coexistence of multiple clear cell papillary renal cell carcinoma with renal oncocytoma: a case report
Amine Hermi, Ahmed Saadi, Seif Mokadem, Ahlem Blel, Marouene Chakroun, Mohamed Riadh Ben Slama
Annals of Medicine & Surgery.2023; 85(5): 2017. CrossRef
Renal Cell Carcinoma in End-Stage Renal Disease: A Review and Update
Ziad M. El-Zaatari, Luan D. Truong
Biomedicines.2022; 10(3): 657. CrossRef
The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management
Stanley Weng, Renzo G. DiNatale, Andrew Silagy, Roy Mano, Kyrollis Attalla, Mahyar Kashani, Kate Weiss, Nicole E. Benfante, Andrew G. Winer, Jonathan A. Coleman, Victor E. Reuter, Paul Russo, Ed Reznik, Satish K. Tickoo, A. Ari Hakimi
European Urology.2021; 79(4): 468. CrossRef
Clear cell papillary renal cell carcinoma: Characteristics and survival outcomes from a large single institutional series
James E. Steward, Sean Q. Kern, Liang Cheng, Ronald S. Boris, Yan Tong, Clint D. Bahler, Timothy A. Masterson, K. Clint Cary, Hristos Kaimakliotis, Thomas Gardner, Chandru P. Sundaram
Urologic Oncology: Seminars and Original Investigations.2021; 39(6): 370.e21. CrossRef
Clear cell papillary renal cell carcinoma: an update after 15 years
Sean R. Williamson
Pathology.2021; 53(1): 109. CrossRef
Clear Cell Papillary Renal Cell Carcinoma
Jianping Zhao, Eduardo Eyzaguirre
Archives of Pathology & Laboratory Medicine.2019; 143(9): 1154. CrossRef
Clear cell papillary renal cell carcinoma – An indolent subtype of renal tumor
Wei-Jen Chen, Chin-Chen Pan, Shu-Huei Shen, Hsiao-Jen Chung, Chih-Chieh Lin, Alex T.L. Lin, Yen-Hwa Chang
Journal of the Chinese Medical Association.2018; 81(10): 878. CrossRef
Clear cell papillary renal cell carcinoma: A case report and review of the literature
Sung Han Kim, Whi-An Kwon, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
World Journal of Nephrology.2018; 7(8): 155. CrossRef
Clinical features and survival analysis of clear cell papillary renal cell carcinoma: A 10‑year retrospective study from two institutions
Yiqiu Wang, Ying Ding, Jian Wang, Min Gu, Zengjun Wang, Chao Qin, Conghui Han, Hongxia Li, Xia Liu, Pengfei Wu, Guangchao Li
Oncology Letters.2018;[Epub] CrossRef
A contemporary series of renal masses with emphasis on recently recognized entities and tumors of low malignant potential: A report based on 624 consecutive tumors from a single tertiary center
Maria Rosaria Raspollini, Ilaria Montagnani, Rodolfo Montironi, Liang Cheng, Guido Martignoni, Andrea Minervini, Sergio Serni, Giulio Nicita, Marco Carini, Antonio Lopez-Beltran
Pathology - Research and Practice.2017; 213(7): 804. CrossRef
Renal Neoplasms With Overlapping Features of Clear Cell Renal Cell Carcinoma and Clear Cell Papillary Renal Cell Carcinoma
Hari P. Dhakal, Jesse K. McKenney, Li Yan Khor, Jordan P. Reynolds, Cristina Magi-Galluzzi, Christopher G. Przybycin
American Journal of Surgical Pathology.2016; 40(2): 141. CrossRef
New and emerging renal tumour entities
Naoto Kuroda, Ondřej Hess, Ming Zhou
Diagnostic Histopathology.2016; 22(2): 47. CrossRef
Immunohistochemical Panel for Differentiating Renal Cell Carcinoma with Clear and Papillary Features
Hanan AlSaeid Alshenawy
Pathology & Oncology Research.2015; 21(4): 893. CrossRef
Immunohistochemical panel for differentiating renal cell carcinoma with clear and papillary features
Hanan AlSaeid Alshenawy
Journal of Microscopy and Ultrastructure.2015; 3(2): 68. CrossRef
Clear Cell-Papillary Renal Cell Carcinoma of the Kidney Not Associated With End-stage Renal Disease
Manju Aron, Elena Chang, Loren Herrera, Ondrej Hes, Michelle S. Hirsch, Eva Comperat, Philippe Camparo, Priya Rao, Maria Picken, Michal Michal, Rodolfo Montironi, Pheroze Tamboli, Federico Monzon, Mahul B. Amin
American Journal of Surgical Pathology.2015; 39(7): 873. CrossRef
Papillary or pseudopapillary tumors of the kidney
Fang-Ming Deng, Max X. Kong, Ming Zhou
Seminars in Diagnostic Pathology.2015; 32(2): 124. CrossRef
Do Clear Cell Papillary Renal Cell Carcinomas Have Malignant Potential?
Mairo L. Diolombi, Liang Cheng, Pedram Argani, Jonathan I. Epstein
American Journal of Surgical Pathology.2015; 39(12): 1621. CrossRef
Targeted next‐generation sequencing and non‐coding RNA expression analysis of clear cell papillary renal cell carcinoma suggests distinct pathological mechanisms from other renal tumour subtypes
Charles H Lawrie, Erika Larrea, Gorka Larrinaga, Ibai Goicoechea, María Arestin, Marta Fernandez‐Mercado, Ondrej Hes, Francisco Cáceres, Lorea Manterola, José I López
The Journal of Pathology.2014; 232(1): 32. CrossRef
Clear cell papillary renal cell carcinoma is the fourth most common histologic type of renal cell carcinoma in 290 consecutive nephrectomies for renal cell carcinoma
Haijun Zhou, Shaojiang Zheng, Luan D. Truong, Jae Y. Ro, Alberto G. Ayala, Steven S. Shen
Human Pathology.2014; 45(1): 59. CrossRef
Clear cell papillary renal cell carcinoma: Incidence, morphological features, immunohistochemical profile, and biologic behavior: A single institution study
Borislav A. Alexiev, Cinthia B. Drachenberg
Pathology - Research and Practice.2014; 210(4): 234. CrossRef
MRI Phenotype in Renal Cancer
Naomi Campbell, Andrew B. Rosenkrantz, Ivan Pedrosa
Topics in Magnetic Resonance Imaging.2014; 23(2): 95. CrossRef

Cyclooxygenase-2 Expression and Its Prognostic Significance in Clear Cell Renal Cell Carcinoma: Ji Won Lee, Jeong Hwan Park, Ja Hee Suh, Kyung Han Nam, Ji-Young Choe, Hae Yoen Jung, Ji Yoen Chae, Kyung Chul Moon; Korean J Pathol. 2012;46(3):237-245. Published online June 22, 2012; DOI: https://doi.org/10.4132/KoreanJPathol.2012.46.3.237

8,458 View
51 Download
16 Crossref

Abstract PDF

Background

The prognostic value of cyclooxygenase-2 (COX-2) in human renal cell carcinoma (RCC) remains unclear. The purposes of this study are to elucidate the clinical significance of COX-2 in clear cell RCC (CCRCC) and to assess the treatment effect of COX-2 inhibition on CCRCC cell lines.

Methods

Using tumor samples obtained from 137 patients who had undergone nephrectomy at Seoul National University Hospital, we evaluated COX-2 expression on immunohistochemistry. Moreover, we performed the cell proliferation assay using 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl-2H tetrazolium bromide (MTT) and cell invasion assay. Thus, we evaluated the effect of meloxicam, an inhibitor of COX-2, in two human CCRCC cell lines.

Results

Cancer-specific survival (p=0.038) and progression-free survival (p=0.031) were shorter in the COX-2 high expression group. A multivariate logistic regression model showed that COX-2 expression was an independent risk factor for pTNM stage and Fuhrman nuclear grade. The MTT assay revealed that COX-2 inhibition led to the suppression of the proliferation of CCRCC cell lines. Moreover, it also reduced their invasion capacity.

Conclusions

This study postulates that COX-2 is a poor prognostic indicator in human CCRCC, suggesting that COX-2 inhibition can be a potential therapy in CCRCC.

Citations

Citations to this article as recorded by

Arachidonic acid metabolism as a therapeutic target in AKI-to-CKD transition
Xiao-Jun Li, Ping Suo, Yan-Ni Wang, Liang Zou, Xiao-Li Nie, Ying-Yong Zhao, Hua Miao
Frontiers in Pharmacology.2024;[Epub] CrossRef
The tumor microenvironment and immune targeting therapy in pediatric renal tumors
Amy B. Hont, Benoit Dumont, Kathryn S. Sutton, John Anderson, Alex Kentsis, Jarno Drost, Andrew L. Hong, Arnauld Verschuur
Pediatric Blood & Cancer.2023;[Epub] CrossRef
Free-fatty acid receptor-1 (FFA1/GPR40) promotes papillary RCC proliferation and tumor growth via Src/PI3K/AKT/NF-κB but suppresses migration by inhibition of EGFR, ERK1/2, STAT3 and EMT
Priyanka F. Karmokar, Nader H. Moniri
Cancer Cell International.2023;[Epub] CrossRef
Flavonoids derived from Anemarrhenae Rhizoma ameliorate inflammation of benign prostatic hyperplasia via modulating COX/LOX pathways
Xiaotong Cao, Ying Shang, Weigui Kong, Shuqing Jiang, Jun Liao, Ronghua Dai
Journal of Ethnopharmacology.2022; 284: 114740. CrossRef
Kirenol, darutoside and hesperidin contribute to the anti-inflammatory and analgesic activities of Siegesbeckia pubescens makino by inhibiting COX-2 expression and inflammatory cell infiltration
Yu-Sang Li, Jian Zhang, Gui-Hua Tian, Hong-Cai Shang, He-Bin Tang
Journal of Ethnopharmacology.2021; 268: 113547. CrossRef
Differential expression of cyclooxygenase-2 and cyclin D1 in salivary gland tumors
Jefferson da Rocha Tenório, Leorik Pereira da Silva, Marília Gabriela de Aguiar Xavier, Thalita Santana, George João Ferreira do Nascimento, Ana Paula Veras Sobral
European Archives of Oto-Rhino-Laryngology.2018; 275(9): 2341. CrossRef
Retrospective evaluation ofCOX‐2 expression, histological and clinical factors as prognostic indicators in dogs with renal cell carcinomas undergoing nephrectomy
S. Carvalho, A. L. Stoll, S. L. Priestnall, A. Suarez‐Bonnet, K. Rassnick, S. Lynch, I. Schoepper, G. Romanelli, P. Buracco, M. Atherton, E. M. de Merlo, A. Lara‐Garcia
Veterinary and Comparative Oncology.2017; 15(4): 1280. CrossRef
Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib
Arancha Cebrián, Teresa Gómez del Pulgar, María José Méndez-Vidal, María Luisa Gonzálvez, Nuria Lainez, Daniel Castellano, Iciar García-Carbonero, Emilio Esteban, Maria Isabel Sáez, Rosa Villatoro, Cristina Suárez, Alfredo Carrato, Javier Munárriz-Ferránd
Scientific Reports.2017;[Epub] CrossRef
COX-2 expression in ovarian cancer: an updated meta-analysis
Haiming Sun, Xuelong Zhang, Donglin Sun, Xueyuan Jia, Lidan Xu, Yuandong Qiao, Yan Jin
Oncotarget.2017; 8(50): 88152. CrossRef
COX-2 Expression in Renal Cell Carcinoma and Correlations with Tumor Grade, Stage and Patient Prognosis
Hedieh Moradi Tabriz, Marzieh Mirzaalizadeh, Shahram Gooran, Farzaneh Niki, Maryam Jabri
Asian Pacific Journal of Cancer Prevention.2016; 17(2): 535. CrossRef
Lipidomic Signatures and Associated Transcriptomic Profiles of Clear Cell Renal Cell Carcinoma
Kosuke Saito, Eri Arai, Keiko Maekawa, Masaki Ishikawa, Hiroyuki Fujimoto, Ryo Taguchi, Kenji Matsumoto, Yae Kanai, Yoshiro Saito
Scientific Reports.2016;[Epub] CrossRef
Intratumoral expression of cyclooxygenase-2 (COX-2) is a negative prognostic marker for patients with cutaneous melanoma
Łukasz Kuźbicki, Dariusz Lange, Agata Stanek-Widera, Barbara W. Chwirot
Melanoma Research.2016; 26(5): 448. CrossRef
New Insights on COX-2 in Chronic Inflammation Driving Breast Cancer Growth and Metastasis
Honor J. Hugo, C. Saunders, R. G. Ramsay, E. W. Thompson
Journal of Mammary Gland Biology and Neoplasia.2015; 20(3-4): 109. CrossRef
The Role of Prostaglandin E2 in Renal Cell Cancer Development: Future Implications for Prognosis and Therapy
Katarzyna Kaminska, Cezary Szczylik, Fei Lian, Anna M Czarnecka
Future Oncology.2014; 10(14): 2177. CrossRef
Genomics and epigenomics of clear cell renal cell carcinoma: Recent developments and potential applications
Małgorzata Rydzanicz, Tomasz Wrzesiński, Hans A.R. Bluyssen, Joanna Wesoły
Cancer Letters.2013; 341(2): 111. CrossRef
Quantitative Assessment of the Association of COX-2 (Cyclooxygenase-2) Immunoexpression with Prognosis in Human Osteosarcoma: A Meta-Analysis
Zhe Wang, Maolin He, Zengming Xiao, Hao Wu, Yang Wu, Dominique Heymann
PLoS ONE.2013; 8(12): e82907. CrossRef

The Expression of Transforming Growth Factor-beta1 and alpha-Smooth Muscle Actin is Increased in the Human Myxomatous Valve.: Jeong Hwan Park, Ho Joong Youn, Jung Sook Yoon, Chul Soo Park, Soo Sung Oh, Woo Baek Chung, Jong Won Chung, Yun Seok Choi, Dong Hyun Lee, Yong Seog Oh, Wook Sung Chung, Soon Jo Hong, Youn Soo Lee, Sung Bo Sim, Sun Hee Lee; Korean J Pathol. 2009;43(2):152-156.; DOI: https://doi.org/10.4132/KoreanJPathol.2009.43.2.152

4,188 View
26 Download
2 Crossref

Abstract PDF

BACKGROUND
In vitro experimental studies have reported that transforming growth factor-beta1 (TGF-beta1) stimulates the production of alpha-smooth muscle actin (alpha-SMA) in porcine valves. However, the relation between TGF-beta1 and alpha-SMA in myxomatous valves has not been elucidated.
METHODS
We classified 27 subjects into two groups: 1) myxomatous group (M:F=11:12, mean age=55+/-15 years) and 2) rheumatic group (M:F=3:1, mean age=41+/-17 years) according to preoperative echocardiographic and postoperative histologic findings. Twenty-seven valve specimens from the patients who underwent valve replacement were obtained. Tissue samples were analyzed by immunohistochemistry for TGF-beta1 and alpha-SMA. The positively stained areas were measured using an image analysis program (Image Pro-Plus 4.5), and then the TGF-beta1 volume fraction (TGF-VF) and alpha-SMA volume fraction (alpha-SMA-VF) were calculated.
RESULTS
TGF-VF in myxomatous valves was higher than in rheumatic valves (2,759+/-2,294 vs 864+/-276, p=0.04). alpha-SMA-VF in myxomatous valves was higher than in rheumatic valves (4,122+/-2,275 vs 2,421+/-844, p=0.002). There was a significant correlation between TGF-beta1 and alpha-SMA in myxomatous valves (r=0.38, p=0.04). There was no significant correlation between TGF-beta1 and alpha-SMA in rheumatic valves (r=-0.50, p=0.67).
CONCLUSIONS
TGF-beta1 and alpha-SMA may be related to the pathogenesis of myxomatous valves. The activation of TGF-beta1 might increase the expression of alpha-SMA in human myxomatous valves.

Citations

Citations to this article as recorded by

Apoptosis and abundance of Bcl-2 family and transforming growth factor β1 signaling proteins in canine myxomatous mitral valves
Sirilak Surachetpong, Treenate Jiranantasak, Anudep Rungsipipat, E. Christopher Orton
Journal of Veterinary Cardiology.2013; 15(3): 171. CrossRef
Pathology, protein expression and signaling in myxomatous mitral valve degeneration: Comparison of dogs and humans
Heike Aupperle, Sirilak Disatian
Journal of Veterinary Cardiology.2012; 14(1): 59. CrossRef

First
Prev
Page of 1
Next
Last

Search